<i>JAMA</i> Study Recommends Better Research Publication

Clinical Trials Advisor
The FDA should make unredacted results of clinical trial site inspections more readily available to the public and to readers and editors of scientific journals, to ensure transparency about tainted studies and potentially bogus drugs, an article in the February JAMA Internal Medicine says.

To View This Article:


Subscribe To Clinical Trials Advisor